ライフサイエンスコーパス: vasculitis

1 serum creatinine concentration attributed to vasculitis).

2 odies responsible for mixed cryoglobulinemic vasculitis.

3 n in vascular tissues in a mouse model of KD vasculitis.

4 is that precedes the development of coronary vasculitis.

5 iltrating T cells and effectively suppressed vasculitis.

6 of atezolizumab-associated AMN with retinal vasculitis.

7 te of neovascularization relapse in ischemic vasculitis.

8 ts had a serious adverse event or relapse of vasculitis.

9 placing muscle fibers, with no granulomas or vasculitis.

10 th the endothelium, resulting in necrotizing vasculitis.

11 roid therapy and sustain chronic, smoldering vasculitis.

12 matosis with polyangiitis is an eosinophilic vasculitis.

13 well defined autoantigen in ANCA-associated vasculitis.

14 contribute to the morbidity and mortality of vasculitis.

15 iate disease in experimental ANCA-associated vasculitis.

16 olved in the pathogenesis of ANCA-associated vasculitis.

17 a control group (1022 eyes) with no retinal vasculitis.

18 lacing high-dose glucocorticoids in treating vasculitis.

19 athogenic mechanisms underlying this type of vasculitis.

20 ase characterized by lymphoproliferation and vasculitis.

21 tion revealed peripheral hemorrhagic retinal vasculitis.

22 sk of macular edema compared to eyes with no vasculitis.

23 anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.

24 cell damage in patients with ANCA-associated vasculitis.

25 o being tightly correlated with active renal vasculitis.

26 e inflammatory disease, such as large-vessel vasculitis.

27 linked ADA2 deficiency with inflammation and vasculitis.

28 ted with development of systemic necrotizing vasculitis.

29 early in the disease course of experimental vasculitis.

30 such as hypertension, stroke, thrombosis and vasculitis.

31 at which time all had a clinical response of vasculitis.

32 are acute febrile illness due to multi-organ vasculitis.

33 arteritis (GCA), a polygenic immune-mediated vasculitis.

34 s; histological findings indicated cutaneous vasculitis.

35 milar to vancomycin-induced leukocytoclastic vasculitis.

36 nt vaccine-induced arthritis, dermatitis, or vasculitis.

37 ytes of patients with active ANCA-associated vasculitis.

38 volvement for the presence of occult retinal vasculitis.

39 dependent venous congestion and inflammatory vasculitis.

40 our understanding of TRALI as a rapid-onset vasculitis.

41 sphagia, pronounced muscle fiber damage, and vasculitis.

42 reatment or even as a trigger for rheumatoid vasculitis.

43 taneous inflammation, e.g., leukocytoclastic vasculitis.

44 tineutrophil cytoplasmic antibody-associated vasculitis.

45 recurrent stroke to systemic vasculopathy or vasculitis.

46 es presenting with a PUK and proven systemic vasculitis.

47 and pulmonary inflammation, chondritis, and vasculitis.

48 -1 in the subsequent development of coronary vasculitis.

49 histopathologic findings of leukocytoclastic vasculitis.

50 plex challenge, they do not develop coronary vasculitis.

51 ffector functions in medium and large vessel vasculitis.

52 y the emergence of life-threatening coronary vasculitis.

53 siology may imply other phenomena, including vasculitis.

54 d amount of suprachoroidal fluid on OCT-EDI (vasculitis, 0.45 [P < .001]; vitreous haze, 0.59 [P < .0

55 ities were commonly noted: retinal occlusive vasculitis (21/77; 27%) and serpiginoid choroiditis (11/

56 omatous optic atrophy eyes (7.9%) (1 retinal vasculitis, 3 papilledema, 2 infiltrative optic neuropat

57 nce of definite/probable IOI was 4.6% (IOI + vasculitis, 3.3%; IOI + vasculitis + occlusion, 2.1%).

58 vitreous haze (523 of 1153 [45.4%]), retinal vasculitis (374 of 874 [42.8%]), and choroidal involveme

59 sence of >/=1 peripheral granulomas (57.1%), vasculitis (57.1%), vitreoretinal traction (57.1%), and

60 ic autoimmune disorders (7472), and systemic vasculitis (6283) and in 373 851 matched controls.

61 onchopneumonia (17/70), and leukocytoclastic vasculitis (7/70).

62 patients with active autoantibody-associated vasculitis, a chronic relapsing autoimmune inflammatory

63 The differences between PR3-ANCA-associated vasculitis (AAV) and MPO-AAV described in the past have

64 Treatment of patients with ANCA-associated vasculitis (AAV) and severe renal involvement is not est

65 ophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) constitutes life-threatening autoimmune

66 ANCA-associated vasculitis (AAV) is a highly inflammatory condition in w

67 murine myeloperoxidase (MPO)-ANCA-associated vasculitis (AAV) show mast cells degranulate, thus enhan

68 emission-induction in severe ANCA-associated vasculitis (AAV), but renal outcomes are unknown.

69 ophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), with rapidly progressive glomeruloneph

70 proteinase-3 (PR3)-positive ANCA-associated vasculitis (AAV).

71 tineutrophil cytoplasmic antibody-associated vasculitis (AAV).

72 tineutrophil cytoplasmic antibody-associated vasculitis (AAV).

73 s achieving a >/=50% reduction in Birmingham Vasculitis Activity Score by week 12 and no worsening in

74 The mean (+/-standard deviation) Birmingham Vasculitis Activity Score decreased from 5.41 (+/-3.53)

75 toms or worsening disease, with a Birmingham Vasculitis Activity Score greater than 0.

76 The 2 remission definitions were Birmingham Vasculitis Activity Score of 0 plus OGC dose of 4 mg/d o

77 fied and weighted adoption of the Birmingham Vasculitis Activity Score.

78 ete remission (CR) was defined as Birmingham Vasculitis Activity Score/Wegener's Granulomatosis (BVAS

79 Failure to control occult retinal vasculitis adequately may be a contributing factor to se

80 is an acute, inflammatory, and self-limited vasculitis affecting infants and young children.

81 i Disease (KD) is the most common paediatric vasculitis affecting small to medium arteries.

82 AMN-like retinopathy with or without retinal vasculitis after atezolizumab administration.

83 Acute Multifocal Hemorrhagic Retinal Vasculitis (AMHRV) is a rare disease with unknown incide

84 In patients with GN or vasculitis, ANCAs are directed against proteinase 3 (PR3

85 oma there was a partial clinical response of vasculitis and approximately 50% decrease of cryocrit, a

86 ers involving severe, systemic, small-vessel vasculitis and are characterized by the development of a

87 are common in patients with primary systemic vasculitis and are seen in vasculitis secondary to disor

88 tic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis.

89 oimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases,

90 ncentration in patients with ANCA-associated vasculitis and controls, and assessed neutrophil extrace

91 well as clear histopathology of necrotizing vasculitis and hemorrhage in the brain.

92 to other IgA-related diseases, including IgA vasculitis and IgA nephropathy.

93 Retinal vasculitis and IOI after brolucizumab IVI are characteri

94 Retinal vasculitis and IOI were diagnosed at a mean of 30 days a

95 Patients with retinal vasculitis and low-grade vitritis with or without macula

96 The kinin system is activated during vasculitis and may contribute to chronic inflammation.

97 asured NGAL in patients with ANCA-associated vasculitis and mice with anti-myeloperoxidase (anti-MPO)

98 ophil cytoplasmic antibody (ANCA)-associated vasculitis and myasthenia gravis were rather disappointi

99 cells by ANCA is central to ANCA-associated vasculitis and necrotizing crescentic glomerulonephritis

100 ANCA-activated phagocytes cause vasculitis and necrotizing crescentic GN (NCGN).

101 vestigated intestinal barrier function in KD vasculitis and observed evidence of intestinal permeabil

102 LCV is a rare form of vasculitis and one of the rarest dermatologic manifestat

103 l therapeutic candidate for Kawasaki disease vasculitis and other IL-1 mediated inflammatory diseases

104 y or trauma, and with negative screening for vasculitis and other systemic autoimmune disease were in

105 es as pivotal in the pathogenesis of cardiac vasculitis and provide evidence about the mechanisms gov

106 acranial vessel wall enhancement between CNS vasculitis and risk factors for intracranial atheroscler

107 ntiferon were diverse, but retinal occlusive vasculitis and serpiginoid choroiditis were common.

108 aques of the coronary arteries, small vessel vasculitis and small aneurysm.

109 pe recognized by ANCA in patients with acute vasculitis and the nephritogenic murine T cell MPO epito

110 rized by necrotizing small- to medium-vessel vasculitis and the presence of anti-neutrophil cytoplasm

111 ting the visual outcome in eyes with retinal vasculitis and the rate of neovascularization relapse in

112 of disease activity measured in this study (vasculitis and vitreous haze) also showed a significant

113 re easily assessed clinical features such as vasculitis and vitreous haze.

114 pillary leakage and ischemia, (3) peripheral vasculitis, and (4) leakage from neovascularization.

115 el associates very tightly with active renal vasculitis, and assessing this level may be a noninvasiv

116 Histopathology revealed leptomeningitis, vasculitis, and focal inflammation in the central nervou

117 ips exist between peripheral vessel leakage, vasculitis, and ischemia, it was only macular ischemia a

118 systemic inflammation, lymphoid hyperplasia, vasculitis, and kidney disease.

119 are a therapeutic target in ANCA-associated vasculitis, and suggest that a molecular hotspot within

120 d events within the spectrum of IOI, retinal vasculitis, and/or vascular occlusion.

121 retinal involvement interpreted as "retinal vasculitis," and improvement of neuroimaging abnormaliti

122 Although cases frequently mimicked vasculitis, angiography was uniformly negative, and spin

123 ons for Acute Multifocal Hemorrhagic Retinal Vasculitis are oral corticosteroids, intravitreal gancic

124 elopment of cardiovascular lesions during KD vasculitis are still unknown.

125 i-neutrophil cytoplasmic antibody-associated vasculitis, as well as in some groups of renal transplan

126 mbranoproliferative GN, lupus nephritis, and vasculitis associated with HRs (95% confidence intervals

127 levels as predictors of aseptic lymphocytic vasculitis-associated lesion (ALVAL) score at histologic

128 CD28 blockade effectively suppressed vasculitis-associated remodeling of the vessel wall.

129 Retinal vasculitis at presentation occurred in 61 eyes (26.3%),

130 have been implicated in the pathogenesis of vasculitis, at least in part, through the formation of n

131 yndrome, bicuspid aortic valve, inflammatory vasculitis, atherosclerosis and infections).

132 serum complement, renal manifestations, and vasculitis, but the latter two of these associations wer

133 ith polyangiitis, and immunoglobulin A (IgA) vasculitis by analysing BCR clonality, use of immunoglob

134 ident case was diagnosed as leukocytoclastic vasculitis by tissue examination.

135 The extent of peripheral vasculitis, capillary nonperfusion, and vessel leakage w

136 l disease, febrile attacks, and small-vessel vasculitis characteristic of Behcet disease.

137 sculitis (LCV) is an immune-complex mediated vasculitis characterized by neutrophilic inflammation an

138 gammaherpesvirus model for producing severe vasculitis, colitis and lethal hemorrhagic pneumonia in

139 (HCV)-associated mixed cryoglobulinemia (MC) vasculitis commonly regresses upon virus eradication, bu

140 n loss was significantly more in the retinal vasculitis compared with the non-vasculitis group (hazar

141 seases, Takotsubo syndrome, arrhythmias, and vasculitis constitute other significant AEs.

142 revealed that patients with ANCA-associated vasculitis could be divided into two groups, on the basi

143 ophil cytoplasmic antibody (ANCA)-associated vasculitis, Crohn's disease, Behcet's disease, eosinophi

144 (HCV) infection, and overt cryoglobulinemia vasculitis (CryoVas) develops in approximately 15% of pa

145 ice and patients with active ANCA-associated vasculitis demonstrated strongly increased serum and uri

146 intestinal barrier function, subsequent IgA vasculitis development, and cardiac inflammation.

147 schemia increased the risk of vision loss in vasculitis eyes by 4.4 times.

148 ANCA-associated vasculitis features necrotizing crescentic GN (NCGN), an

149 To identify novel biomarkers of renal vasculitis flare, we analysed the longitudinal urinary m

150 ar eruptions and livedo, necrosis, and other vasculitis forms have been reported most frequently in a

151 fic biomarker that can separate active renal vasculitis from other causes of renal dysfunction is lac

152 typical PDNS lesions, including necrotizing vasculitis, glomerulonephritis, granulomatous lymphadeni

153 ials to treat conditions such as hepatitis C vasculitis, graft-versus-host disease, type 1 diabetes,

154 the retinal vasculitis compared with the non-vasculitis group (hazard ratio [HR] 1.67, 95% confidence

155 he risk of macular edema compared to the non-vasculitis group.

156 s post-immunisation, we found that rats with vasculitis had a significantly different urinary metabol

157 atients with SVV, patients with active renal vasculitis had markedly higher urinary sCD163 levels tha

158 st mortality rates and patients with IgAN or vasculitis had the lowest allograft failure rates.

159 Retinal vasculitis had twice the risk of macular edema compared

160 Remission of vasculitis has been associated with viral clearance, but

161 xperimental mouse models of Kawasaki disease vasculitis has considerably improved our understanding o

162 ne storm," hemostasis alterations and severe vasculitis have all been reported to occur with COVID-19

163 h hepatitis C virus-induced cryoglobulinemia vasculitis (HCV-CV).

164 port a case of hemorrhagic occlusive retinal vasculitis (HORV) after prophylactic intracameral vancom

165 nd outcomes of hemorrhagic occlusive retinal vasculitis (HORV).

166 pus nephritis (HR, 0.69; 95% CI, 0.66-0.71), vasculitis (HR, 0.66; 95% CI, 0.61-0.70), DN (HR, 0.50;

167 .32; 95% CI, 1.16 to 1.51), and secondary GN/vasculitis (HR, 1.18; 95% CI, 1.02 to 1.37) than ESKD du

168 upus nephritis [HR,0.91; 95% CI, 0.86-0.97], vasculitis [HR, 0.85; 95% CI, 0.76-0.94), DN [HR, 0.73;

169 suffering from immune complex (IC)-mediated vasculitis (ICV).

170 ation occurred in 61 eyes (26.3%), occlusive vasculitis in 59 eyes (25.4%), and macular edema in 42 e

171 e the mechanisms of chronic inflammation and vasculitis in a child lacking IL-17RA and ADA2 to identi

172 arteritis (GCA) is the most common systemic vasculitis in elderly individuals.

173 l arteritis (GCA) is the most common form of vasculitis in individuals older than 50 years in Western

174 gnificantly reduced scores for tubulitis and vasculitis in the grafts of these recipients.

175 ippling chronic skeletal muscle myositis and vasculitis in the model.

176 ecular profiles, and lesions of arteriolitis/vasculitis in the setting of T cell-mediated rejection (

177 d mesenteric polyarteritis-nodosa (PAN)-like vasculitis in their life span, some as early as 4 months

178 step in the emergence of subsequent cardiac vasculitis in this experimental model.

179 tis (GCA) is the most common type of primary vasculitis in Western countries.

180 Kawasaki disease (KD) is an acute pediatric vasculitis in which host genetics influence both suscept

181 crovascular inflammation and the presence of vasculitis (in 60.5%), interstitial hemorrhages (31.6%),

182 ls from patients with active ANCA-associated vasculitis, indicating that increased transcription resu

183 authors examined how CD28 signaling affects vasculitis induction and maintenance, and which pathogen

184 ent with severe WAS manifesting as cutaneous vasculitis, inflammatory arthropathy, intermittent polyc

185 aglandular systemic complications of SS (ie, vasculitis, interstitial nephritis) were also more commo

186 ts was performed with a focus on lymphocytic vasculitis, intravascular fibrin, vessel caliber, extent

187 Hemorrhagic occlusive retinal vasculitis is a rare, potentially devastating condition

188 In conclusion, our study suggests that IgA vasculitis is an archetypal HLA class II disease.

189 ANCA-associated vasculitis is an autoimmune condition characterized by v

190 Retinal vasculitis is associated with an increased risk of visio

191 genetic component of Immunoglobulin-A (IgA) vasculitis is still far to be elucidated.

192 ANCA-associated vasculitis is the most frequent cause of crescentic GN.

193 Rheumatoid vasculitis is the most serious extra-articular complicat

194 plays a mechanistic role in ANCA-associated vasculitis is unknown.

195 on associated with aneurysms in large vessel vasculitis is unknown.

196 iously known as CECR1) results in a systemic vasculitis known as deficiency of ADA2 (DADA2).

197 rent biomarkers of renal disease in systemic vasculitis lack predictive value and are insensitive to

198 Leukocytoclastic vasculitis (LCV) is an immune-complex mediated vasculiti

199 ions on clinical examination but had retinal vasculitis, low-grade to moderate vitritis, and hypocyan

200 eritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features.

201 detect vascular inflammation in large-vessel vasculitis (LVV).

202 roxidase deposition, seen in ANCA-associated vasculitis, may enhance crescentic GN through antigen-sp

203 (i.e., cell infiltrates including abscesses, vasculitis, meningoencephalitis, and/or ependymitis; n =

204 case histories of two patients who developed vasculitis mimicking polyarteritis nodosa and giant cell

205 1 peptide S-7 improved survival in the MHV68 vasculitis model, whereas an inverse S-7 peptide was ina

206 rescent formation in a renal ANCA-associated vasculitis model.

207 Kawasaki disease is a vasculitis most commonly afflicting children <5 years of

208 s trigger of paralyzing systemic necrotizing vasculitis most severely affecting skeletal muscle, driv

209 emic lupus erythematosus (n = 3,951), and/or vasculitis (n = 5,199), and no prior CVD.

210 subsequently excluded (n=17), and history of vasculitis (n=11).

211 ed with controls (n=15), patients with acute vasculitis (n=12) had markedly higher levels of circulat

212 onic paralyzing myositis and skeletal muscle vasculitis, not cardiomyopathy or gastrointestinal disea

213 leukocytes of patients with ANCA-associated vasculitis observed longitudinally (n=82) and of healthy

214 ters) in eyes with IOI (7 in eyes with IOI + vasculitis + occlusion).

215 IOI was 4.6% (IOI + vasculitis, 3.3%; IOI + vasculitis + occlusion, 2.1%).

216 case of Acute Multifocal Hemorrhagic Retinal Vasculitis occurring in a child.

217 e affected in PR3-AAV, whereas renal limited vasculitis occurs more often in patients with MPO-AAV.

218 cr2(pos) macrophages (and the development of vasculitis) occurs in close proximity to a population of

219 Kawasaki disease is an acute vasculitis of childhood that leads to coronary artery an

220 Kawasaki disease (KD) is the most recognized vasculitis of childhood.

221 ID), both of which present with inflammatory vasculitis of large and medium size arteries.

222 While KD is known to cause vasculitis of medium-sized vessels, few studies have bee

223 ngs of eosinophil-infiltrating granulomatous vasculitis of the skin accompanied by notable peripheral

224 emorrhage, and is especially associated with vasculitis of the skin, but the mechanisms that regulate

225 ase is an acute febrile illness and systemic vasculitis of unknown aetiology that predominantly affli

226 Kawasaki disease is an acute, self-limited vasculitis of unknown etiology that occurs predominantly

227 o show additional evidence of occult retinal vasculitis on FA.

228 he overall 100% rate of clinical response of vasculitis, on an intention-to-treat basis, opens the pe

229 adult patients presenting with undefined CNS vasculitis or a leukodystrophy with prominent neuropsych

230 mic lupus erythematosus, systemic sclerosis, vasculitis or idiopathic inflammatory myopathies.

231 sease, hyperlipidemia, hypertension, retinal vasculitis or inflammation, and systemic lupus erythemat

232 should be evaluated for concomitant retinal vasculitis or retinal vascular occlusive events.

233 s of intraocular inflammation (IOI), retinal vasculitis, or retinal vascular occlusion in patients wi

234 edictors, therapy and outcomes of rheumatoid vasculitis over the past decade.

235 308 IgA vasculitis patients and 1,018 healthy controls from Spai

236 ix consecutive patients with ANCA-associated vasculitis, positive for either proteinase 3 (PR3)-ANCA

237 retinopathy, inflammatory occlusive retinal vasculitis, post-H1N1 vaccine, hypertensive retinopathy,

238 Six of 14 patients had vasculitis pre-HSCT.

239 nosis, location of inflammation, presence of vasculitis, prior immunomodulatory treatments, duration

240 lved, including thromboembolism and cerebral vasculitis, promoted by a systemic bacteremia-mediated i

241 ated leakage (r = 0.462, P = .001) and focal vasculitis (r = 0.441, P = .001).

242 nrolled in the Rituximab for ANCA-Associated Vasculitis (RAVE) Trial who had renal involvement (biops

243 al, adults with newly diagnosed or relapsing vasculitis received placebo plus prednisone starting at

244 two hours were most strongly associated with vasculitis-related factors.

245 Rheumatoid vasculitis remains a rare yet challenging extra-articula

246 mol creatinine for detection of active renal vasculitis resulted in a sensitivity of 83%, specificity

247 onset of visual loss associated with retinal vasculitis, retinal hemorrhage, non-confluent posterior

248 cular complications in patients with retinal vasculitis (RV).

249 primary systemic vasculitis and are seen in vasculitis secondary to disorders such as rheumatoid art

250 Patients with symptoms suggestive of this vasculitis should be evaluated for the presence of nonbl

251 aureus and chronic inflammatory disease and vasculitis since early childhood, which were refractory

252 ons with crescents, mimicking a small vessel vasculitis such as ANCA-associated GN, are a very rare m

253 lnerable to NK cell injury during autoimmune vasculitis, such as granulomatosis with polyangiitis (GP

254 bservations in patients with ANCA-associated vasculitis suggest that CD8(+) T cells participate in di

255 ed glomeruli from patients with small vessel vasculitis (SVV) had markedly higher levels of CD163 mRN

256 lating cryoglobulin associated with systemic vasculitis symptoms.

257 i-neutrophil cytoplasmic antibody-associated vasculitis, systemic lupus erythematosus, idiopathic pul

258 3.3 [2.1-6.1]; P=0.01) and in patients with vasculitis than in those referred for other indications.

259 (ANCA)-associated necrotizing granulomatous vasculitis that affects small to medium size vessels.

260 EGPA is an extremely rare vasculitis that develops several years after preceding a

261 polyangiitis (GPA) is a systemic necrotizing vasculitis that is associated with granulomatous inflamm

262 D) or mucocutaneous lymph node syndrome is a vasculitis that mostly occurs in young children.

263 Kawasaki disease (KD) is a multisystem vasculitis that predominantly targets the coronary arter

264 Kawasaki disease is an acute vasculitis that primarily affects children younger than

265 from suspected central nervous system (CNS) vasculitis to extrapyramidal to cognitive phenotypes.

266 equelae, ranging from cutaneous and visceral vasculitis to glomerulonephritis and B-cell non-Hodgkin

267 It may span from peripheral vasculitis to occlusion of large retinal arteries around

268 mages were obtained in 63 eyes with ischemic vasculitis to quantify area of nonperfusion measured as

269 lar panuveitis (TPU), and tubercular retinal vasculitis (TRV) administered by the experts, after whic

270 Urticarial vasculitis (UV) is a difficult-to-treat condition charac

271 ere performed to rule out vitreitis, retinal vasculitis, vitreous hemorrhage, and systemic amyloidosi

272 alent, 20/53) and VA at diagnosis of retinal vasculitis was 0.981 logMAR (Snellen equivalent, 20/191;

273 nguishable, whereas Grade I with lymphocytic vasculitis was an easy and reproducible histologic findi

274 he use of systemic prednisolone in eyes with vasculitis was associated with a reduced risk of vision

275 In all the families, vasculitis was caused by recessive mutations in CECR1, t

276 Evidence of thrombosis and vasculitis was detected in mice with severe pneumonia.

277 Vasculitis was induced by transferring peripheral blood

278 Retinal vasculitis was observed in 236 eyes (121 ischemic, 115 n

279 noblot (P = .006), and increased when venous vasculitis was present initially (P = .019).

280 Bilateral panuveitis associated with retinal vasculitis was the most common manifestation.

281 er detectable, myositis completely resolved, vasculitis was ~80% reduced, fibrosis was reduced, and m

282 t knowledge on the genetic component of this vasculitis we performed the first genome-wide associatio

283 ession and disease status in ANCA-associated vasculitis, we measured gene-specific DNA methylation of

284 ff rejection and Grade I without lymphocytic vasculitis were almost indistinguishable, whereas Grade

285 eral neuropathy, interstitial nephritis, and vasculitis were more common in those with vision-threate

286 ost altered in rats with active or relapsing vasculitis were trimethylamine N-oxide (TMAO), citrate a

287 or uveitis manifestations (vitreous haze and vasculitis) were more common in the older age group (p =

288 s with polyangiitis (eGPA) is a small-vessel vasculitis where 40% of patients present with serum anti

289 of N1 amplitude were associated with venous vasculitis, whereas lower P1 amplitude values correlated

290 lateral Acute Multifocal Hemorrhagic Retinal Vasculitis, which later on progressed bilaterally.

291 HLA-DQ association with MPO+ ANCA-associated vasculitis, while ANCA-negative EGPA may instead have a

292 ld with Acute Multifocal Hemorrhagic Retinal Vasculitis who was treated with aggressive immunosuppres

293 Behcet disease (BD) is a systemic vasculitis with a broad range of organ involvement, char

294 with polyangiitis (EGPA) is a rare systemic vasculitis with a prevalence rate of seven per million.

295 severe Acute Multifocal Hemorrhagic Retinal Vasculitis with aggressive immunosuppressive agents in c

296 are two major autoantigens in patients with vasculitis with ANCA.

297 izumab injection identified signs of retinal vasculitis with or without retinal vascular occlusion an

298 association of hemorrhagic occlusive retinal vasculitis with vancomycin and the commercial unavailabi

299 r regions of the brain there was evidence of vasculitis, with perivascular infiltrates of inflammator

300 s with mild to moderate vitritis and retinal vasculitis without definite birdshot lesions on clinical